Matches in SemOpenAlex for { <https://semopenalex.org/work/W2884353653> ?p ?o ?g. }
- W2884353653 endingPage "10" @default.
- W2884353653 startingPage "1" @default.
- W2884353653 abstract "Purpose Microsatellite instable-high (MSI-H) colorectal cancers (CRCs) are known to carry better survival in the local disease stage even without treatment. The influence of types of treatment on survival of MSI-H metastatic CRCs (mCRCs) is still unclear and is evaluated in this study. Materials and Methods Patients with MSI-H mCRC treated with first-line chemotherapy, with or without bevacizumab, identified in the Israeli population-based Molecular Epidemiology of Colorectal Cancer (MECC) study, were diagnosed between 1998 and 2013 and followed up until May 2017; MSI status was determined by comparing 10 markers in tumor and normal tissue. Dates of metastases and death and treatment details were extracted from oncology records. Results Among 590 patients treated for mCRC, 106 (18%) had MSI-H tumors. Patients with MSI-H had a median overall survival (OS, from start of first-line treatment) of 1.6 years. The presence of a somatic B-Raf proto-oncogene ( BRAF) mutation was a significant adverse prognostic factor in the MSI-H group (hazard ratio [HR], 1.8; 95% CI, 1.1 to 3.0; P = .026). MSI-H tumors without BRAF mutation (n = 87) had similar OS benefit from fluorouracil (FU) only as from any combination protocols (HR, 0.93; P = .78), whereas microsatellite-stable (MSS) tumors without BRAF mutation (n = 456) showed improved OS over FU-only regimens when combination chemotherapy with or without bevacizumab was used (HR, 0.58; P < .01; P value for interaction = .07). Patients with MSI-H/BRAF wild type (WT) had survival advantage over patients with MSS disease (adjusted HR, 0.58; 95% CI, 0.35 to 0.98) when treated with FU-only protocols. Conclusion Clinical outcomes differ substantially between patients with MSS/BRAF-WT mCRC and MSI-H/BRAF-WT mCRC, with measurable differences between chemotherapy regimens. MSI-H mCRCs are a clinically distinct subset of colorectal cancers. Their current poor outcome suggests that new clinical trials are needed to identify therapeutic options, potentially taking advantage of the new developments in the field of immunotherapy." @default.
- W2884353653 created "2018-08-03" @default.
- W2884353653 creator A5005524023 @default.
- W2884353653 creator A5034362238 @default.
- W2884353653 creator A5060473049 @default.
- W2884353653 creator A5066518394 @default.
- W2884353653 creator A5070703103 @default.
- W2884353653 creator A5085891308 @default.
- W2884353653 creator A5091852443 @default.
- W2884353653 date "2018-11-01" @default.
- W2884353653 modified "2023-10-10" @default.
- W2884353653 title "Outcomes of Chemotherapy for Microsatellite Instable–High Metastatic Colorectal Cancers" @default.
- W2884353653 cites W1504535992 @default.
- W2884353653 cites W1663153674 @default.
- W2884353653 cites W1926715094 @default.
- W2884353653 cites W1934094702 @default.
- W2884353653 cites W1992151729 @default.
- W2884353653 cites W1994943514 @default.
- W2884353653 cites W1997493715 @default.
- W2884353653 cites W2006266845 @default.
- W2884353653 cites W2007420407 @default.
- W2884353653 cites W2013475854 @default.
- W2884353653 cites W2013891525 @default.
- W2884353653 cites W2035324074 @default.
- W2884353653 cites W2051288425 @default.
- W2884353653 cites W2051550002 @default.
- W2884353653 cites W2055732173 @default.
- W2884353653 cites W2060978652 @default.
- W2884353653 cites W2070975285 @default.
- W2884353653 cites W2077428590 @default.
- W2884353653 cites W2085717627 @default.
- W2884353653 cites W2094599623 @default.
- W2884353653 cites W2104580737 @default.
- W2884353653 cites W2108468456 @default.
- W2884353653 cites W2115899284 @default.
- W2884353653 cites W2120921373 @default.
- W2884353653 cites W2123636561 @default.
- W2884353653 cites W2127951115 @default.
- W2884353653 cites W2128793721 @default.
- W2884353653 cites W2131573440 @default.
- W2884353653 cites W2134142320 @default.
- W2884353653 cites W2138970634 @default.
- W2884353653 cites W2140143664 @default.
- W2884353653 cites W2140492933 @default.
- W2884353653 cites W2141285914 @default.
- W2884353653 cites W2144288964 @default.
- W2884353653 cites W2147873693 @default.
- W2884353653 cites W2168680994 @default.
- W2884353653 cites W2171259849 @default.
- W2884353653 cites W2259826353 @default.
- W2884353653 cites W2263970671 @default.
- W2884353653 cites W2337299291 @default.
- W2884353653 cites W2346922868 @default.
- W2884353653 cites W2391651292 @default.
- W2884353653 cites W2416227596 @default.
- W2884353653 cites W2622499649 @default.
- W2884353653 cites W2739132742 @default.
- W2884353653 doi "https://doi.org/10.1200/po.17.00253" @default.
- W2884353653 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7446482" @default.
- W2884353653 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32913995" @default.
- W2884353653 hasPublicationYear "2018" @default.
- W2884353653 type Work @default.
- W2884353653 sameAs 2884353653 @default.
- W2884353653 citedByCount "12" @default.
- W2884353653 countsByYear W28843536532020 @default.
- W2884353653 countsByYear W28843536532021 @default.
- W2884353653 countsByYear W28843536532022 @default.
- W2884353653 countsByYear W28843536532023 @default.
- W2884353653 crossrefType "journal-article" @default.
- W2884353653 hasAuthorship W2884353653A5005524023 @default.
- W2884353653 hasAuthorship W2884353653A5034362238 @default.
- W2884353653 hasAuthorship W2884353653A5060473049 @default.
- W2884353653 hasAuthorship W2884353653A5066518394 @default.
- W2884353653 hasAuthorship W2884353653A5070703103 @default.
- W2884353653 hasAuthorship W2884353653A5085891308 @default.
- W2884353653 hasAuthorship W2884353653A5091852443 @default.
- W2884353653 hasBestOaLocation W28843536532 @default.
- W2884353653 hasConcept C104317684 @default.
- W2884353653 hasConcept C121608353 @default.
- W2884353653 hasConcept C126322002 @default.
- W2884353653 hasConcept C143998085 @default.
- W2884353653 hasConcept C180754005 @default.
- W2884353653 hasConcept C207103383 @default.
- W2884353653 hasConcept C2776694085 @default.
- W2884353653 hasConcept C2777802072 @default.
- W2884353653 hasConcept C2779767149 @default.
- W2884353653 hasConcept C2908647359 @default.
- W2884353653 hasConcept C44249647 @default.
- W2884353653 hasConcept C526805850 @default.
- W2884353653 hasConcept C55493867 @default.
- W2884353653 hasConcept C61320498 @default.
- W2884353653 hasConcept C71924100 @default.
- W2884353653 hasConcept C86803240 @default.
- W2884353653 hasConcept C90924648 @default.
- W2884353653 hasConcept C99454951 @default.
- W2884353653 hasConceptScore W2884353653C104317684 @default.
- W2884353653 hasConceptScore W2884353653C121608353 @default.
- W2884353653 hasConceptScore W2884353653C126322002 @default.